cardiovascular disease
-
Pfizer bows out of developing cardio drug, returns rights to Ionis Pharmaceuticals
After reviewing Phase 2B clinical data, the New York drugmaker and its partner Ionis Pharmaceuticals announced that Pfizer was abandoning the development of a cardiovascular drug, thereby returning the rights to Ionis.
-
Foresite and GV pour $40M into startup’s move to CHIP into new disease biology
TenSixteen Bio has emerged from stealth aiming to develop drugs for diseases caused by genetic mutations accumulated as we age. The startup has been incubating within Foresite Labs and it now has $40 million to finance its research into this new realm of biology.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Pharma, Health Services, Health Tech
Bayer, One Drop release digital health program for heart disease
The app lets people track their metrics through connected devices, and access health coaching and educational materials. It’s one of multiple that Bayer and One Drop plan to develop together in the future.
-
How CVS Caremark plans to address health disparities
CVS Caremark recently launched efforts to better prevent, detect and treat sickle cell disease, HIV and cardiovascular disease. CVS Caremark CMO Sree Chaguturu shared how the PBM launched this effort at the engagement track at HLTH, hosted by MedCity News
-
Artificial Intelligence, BioPharma
ShouTi secures $100M to hit biologic and peptide targets with small molecules
ShouTi Pharmaceuticals, a startup that brings computational techniques to drug discovery, has raised $100 million in Series B financing. The clinical-stage biotech designs small molecules intended to do the work of biologic and peptide drugs.
-
Merck to buy Acceleron for $11.5B; cardio drug could cushion fall from Keytruda cliff
Merck is looking for products that diversify its portfolio beyond reliance on cancer drug Keytruda, and it sees a potential blockbuster cardiovascular drug from Acceleron Pharma as fitting the bill. The pharma giant is paying $11.5 billion to acquire the biotech, and executives say they’re still on the hunt for more deals.
-
Novo Nordisk cardio push picks up Phase 2-ready Prothena drug in $100M deal
Novo Nordisk is paying $100 million up front to acquire an experimental Prothena drug being developed to treat heart problems stemming from a misfolded protein. The deal is part of a broader strategy to expand into drugs for cardiovascular disease.
-
Lyell, Verve IPOs raise a combined $692M as both biotechs steer toward clinical trials
Lyell Immunopharma and Verve Therapeutics are still preclinical, but they’re bringing novel genetic approaches to the treatment of cancer and cardiovascular disease. Now the two companies can claim two of the biggest biotech IPOs of 2021 so far.
-
FDA approves Regeneron drug for rare, inherited form of high cholesterol
The FDA approval clears Regeneron’s drug, Evkeeza, as a treatment for the rarer of two forms of an inherited disease that causes high cholesterol levels. The company already markets Praluent, which treats the more common form of familial hypercholesterolemia.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
$200M investment to advance clinical programs for Ambrx
The San Diego-based biopharma firm has several oncology therapies in development and has partnered in the past with the likes of Astellas, BeiGene and Bristol-Myers Squibb.
-
BMS acquires MyoKardia, maker of drugs for cardiovascular disease, for $13.1B
The companies expect the deal to close in the fourth quarter. MyoKardia’s lead drug candidate is mavacamten, which it is developing for hypertrophic cardiomyopathy and plans to submit to the FDA in the first quarter of next year.
-
FDA approves Esperion’s non-statin cholesterol-lowering drug
The drug, Nexletol, is designed for use with maximally tolerated statins for lowering LDL cholesterol in patients with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease.
-
Devices & Diagnostics, Artificial Intelligence
Eko wins FDA clearance for heart murmur, Afib algorithm
The algorithm is not designed to replace consumer-facing devices. But while most smart watches track electrical signals from the heart, Eko focuses on sound as a means to improve the work of front-line clinicians.
-
Artificial Intelligence, Diagnostics
Startup says algorithm identifies new risk factor for heart disease but a doctor is skeptical
The algorithm — which measures variations in heart rate — is designed to predict heart problems, but a cardiologist wonders whether it can outperform other risk factors.
-
Regeneron scores Phase III win with drug for rare cholesterol disorder
An analyst wrote that while the data are positive, the bigger question is how the drug will be priced, based on another drug already on the market for the same disease, HoFH, which affects about 1,300 people in the U.S.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
